Improvements in eosinophil numbers, asthma control, and FEV1 were maintained for 8 weeks after the last infusion, and no serious adverse events were reported.

• 在最后一次注射后的八周内持续改善了嗜酸粒细胞数、哮喘症状的控制、及FEV1，而且没有报告严重副作用。